What is Cell > Point?
Cell > Point is a biopharmaceutical company dedicated to the advancement of universal molecular imaging compounds and molecular therapeutics. Its core focus lies in developing innovative solutions for the diagnosis, staging, treatment, and monitoring of cancer, cardiovascular disease, and various ischemic conditions. The company leverages exclusive licenses for five drug-development platforms sourced from The University of Texas MD Anderson Cancer Center, a globally recognized leader in cancer research and care. CellPoint holds 59 issued patents for its Oncardia® platform, with an additional 14 patents pending, and is actively pursuing further patent filings related to its novel organic formulation, including a one-vial kit. This robust intellectual property portfolio positions Cell > Point at the forefront of medical innovation.
How much funding has Cell > Point raised?
Cell > Point has raised a total of $226K across 2 funding rounds:
Debt
$150K
Debt
$76K
Debt (2020): $150K with participation from PPP
Debt (2021): $76K led by PPP
What's next for Cell > Point?
With its recent substantial expansion capital, Cell > Point is poised for significant growth and development. The company's late-stage funding context suggests a strategic push towards clinical validation, potential commercialization, and scaling of its proprietary platforms. Future endeavors will likely involve advancing its pipeline of imaging compounds and therapeutics through rigorous testing and regulatory pathways. The company's focus on critical disease areas like cancer and cardiovascular conditions, combined with its strong IP foundation, indicates a strategic direction aimed at capturing significant market share and making a tangible impact on patient outcomes.
See full Cell > Point company page
